Recurrent Bordetella holmesii bacteremia and nasal carriage in a patient receiving rituximab.
Liem Binh Luong
LB
Nguyen
Loïc
L
Epelboin
Jean
J
Gabarre
Marylin
M
Lecso
Sophie
S
Guillot
François
F
Bricaire
Eric
E
Caumes
Nicole
N
Guiso
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016470:Bacteremia / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D001884:Bordetella / Q000302:isolation & purification*; D001885:Bordetella Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D002353:Carrier State; D002481:Cellulitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D060046:Maintenance Chemotherapy; D008297:Male; D009666:Nose / Q000382:microbiology*; D012008:Recurrence; D000069283:Rituximab; D017211:Treatment Failure
D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
Bordetella holmesii; bacteria; cellulitis; pneumonia; respiratory infections; rituximab